Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

202 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-15

Study Completion Date

2024-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radioembolization is an established treatment option for patients with unresectable primary and secondary liver tumors. Microspheres containing 90Y are injected intraarterially to deliver a high radiation dose to the tumors. Despite of our knowledge on the effectiveness of 90Y glass microspheres in the treatment of HCC, literature data on the treatment of metastatic colorectal cancer (mCRC) patients with 90Y glass microspheres is limited. In the recent EANM guideline variable healthy liver doses are recommended for patients with mCRC with an effective tumor dose recommendation based on a study with limited number of patients.

Primary objectives; Investigate effective tumor dose and safe healthy liver dose in radioembolization for colorectal cancer liver metastasis using multicompartment dosimetry Secondary objectives; Investigate dose-response and dose-toxicity relationships, time to progress, concordance between pretreatment and posttreatment dose calculations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Streamlining Radioembolization for CCC and Metastatic Liver Cancer

NCT07043387

Metastatic Colorectal Carcinoma (mCRC) Metastatic Liver Cancer Cholangiocarcinoma

RECRUITING

Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma

NCT07043348

Intrahepatic Cholangiocarcinoma (Icc)

TERMINATED

TheraSphere® For Treatment of Metastases in Liver

NCT04517643

Colorectal Cancer Metastatic Colorectal Cancer

COMPLETED NA

A Prospective Observational Study on Efficacy of TARE for Early Stage HCC

NCT07278102

Radioembolization Hepatocellular Carcinoma (HCC) Early Stage

ACTIVE_NOT_RECRUITING

A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)

NCT07252323

Carcinoma Hepatocellular Carcinoma

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transarterial Radioembolization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation group

Patients who received radioembolization for colorectal cancer liver metastases

Therasphere

Intervention Type DEVICE

Transarterial radioembolization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Therasphere

Transarterial radioembolization

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* over 18 years old
* histopathologically proven colorectal cancer diagnosis
* treated with radioembolization for liver metastases with Y90 glass microspheres in lobar or segmental fashion
* have follow-up data at least 6 months after radioembolization

Exclusion Criteria

* no PET-CT, CT or MR of the liver within last 6 weeks prior to radioembolization.

No PET-CT, CT or MR of the liver 2-4 months after radioembolization Poor image quality Previous local treatment or surgery for the liver

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No